Register
Login:
Share:
Email Facebook Twitter


Angus Energy announces transformational joint venture with Cuadrilla & Lucas Energy
Aim-listed Mongolian explorer Petro Matad to drill four wells in 2018


Sareum Share Chat (SAR)



Share Price: 0.975Bid: 0.95Ask: 1.00Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.05Spread as %: 5.26%Open: 0.95High: 0.975Low: 0.95Yesterday’s Close: 0.975


Share Discussion for Sareum


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Num4
Posts: 1,159
Off Topic
Opinion:No Opinion
Price:0.975
RE: 1.04p
Today 08:23
Indeed. I'm expecting more for PII since the upfront and transfer was small in comparison to other deals.
Now they know it works as per pre-clinical data and they have a blockbuster, time to pay up.
 
Stoney40
Posts: 696
Off Topic
Opinion:No Opinion
Price:0.975
RE: 1.04p
Sat 21:38
I think Thoth has called it right....the details of milestones will have to be in the Sierra annual report listed as liabilities. I

Num4 - if we are missing 12m it's just makes Thoths numbers higher :-)
Num4
Posts: 1,159
Off Topic
Opinion:No Opinion
Price:0.975
RE: 1.04p
Sat 19:08
Thoth, I think you've lost 12million somewhere, $88.4million was the amount due in milestones, we've had 2million. So $86.4million due.
boss007
Posts: 1,030
Question
Opinion:Strong Buy
Price:0.975
RE: 1.04p
Sat 15:08
Hi Thoth. Hope u are ok mate. How happy are you with progress of chk1 ? Is it better than u thought? Looks like lots of combo potential , hopefully lots of milestones.

Thanks for u views
Thoth2
Posts: 1,819
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.975
RE: 1.04p
Sat 13:31
Num4- my guesstimate breakdown is
P2 $8m
P3 $16m
NDA $25m
marketing approval $25m
and Sierra will need to raise loads of cash, as they will need to fund any parp combo trials as well, which is probably depressing their SP. Their annual report should be c 3rd March, which may give an indication of a provision for our next milestone.
Thoth2
Posts: 1,819
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.975
View Thread (3)
RE: 1.04p
Sat 13:28
Its on the sierra website. or you can listen to the webcast
http://investor.sierraoncology.com/events-and-webcasts?item=23
The monotherapy is already in P2, and the combo about to move into P2. They seem to have amended the trial so that it is now a P1/2 rather than just P1. whether we have a subsequent P2b we dont know.
stevej
Posts: 6,797
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.975
RE: 1.04p
Sat 11:55
Have I missed something about us being in Phase 2 as I thought phase one was listed to be finished April 19?

Appreciate the link in phase 2
Num4
Posts: 1,159
Off Topic
Opinion:No Opinion
Price:0.975
RE: 1.04p
Fri 22:54
Thoth, what breakdown would you give the deal for chk1?
Are you expecting announcement from Sierra to include funding details going forward, they need another £100 million minimum to get the trials progressed and others started, thats also with the hope they can get commercial sales during the trials due to breakthrough announcement.
Thoth2
Posts: 1,819
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.975
RE: 1.04p
Fri 22:11
Aimsurfer. A couple of adjustments to your calcs.
As we are now in p2. Entering p3 looks probable with c £12m milestone attached.
5 years is a reasonable average. But in diseases with no treatment optons available and poor prognosis (which criteria we meet in spades) its possible to be prescribed after p1. Lets see what clues we get on tuesday.
potnak
Posts: 969
Off Topic
Opinion:No Opinion
Price:0.975
RE: Who sold ?9500
Fri 16:48
The program update is on Tuesday. There won't be any news on Monday. Remember though, this is just an update, what we are looking for here is any talk of efficacy and talk of moving to PII. The latter could generate a milestone payment to SAR. If so we'll get an RNS after the presentation or on Wednesday morning. Then we wait for our interims which I expect to be blah blah blah but it is hotting up in here.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.